facebook pixel Phone 212 693 530* *Fixed network call charges according to your tariff Search for your nearest Collection Point

212 693 530*

Collection Points

Phone 212 693 530* *Fixed network call charges according to your tariff

Cancer and Genetics

Cancer and genetics are inextricably linked: cancer essentially results from the accumulation of errors in our DNA that compromise cell function and enable them to exhibit oncogenic behavior. Thus, the study of these errors and the “genetics” of cancer is essential to our deeper understanding of and approach to the disease, with applications ranging from prevention to treatment. 

In the field of prevention, there are currently well-established strategies—such as the diagnosis of genetic predisposition to familial cancer—and emerging ones—such as the early diagnosis of cancer through liquid biopsies. 

Genetic predisposition to familial cancer results from the presence of a pathogenic germline variant (mutation)—present in sex cells and therefore inherited and distributed throughout the body— in key genes (important for DNA repair, tumor suppressors, and oncogenes). The disruption of these genes’ function thus promotes the emergence of further errors and facilitates the development of the disease. 

It is estimated that, globally, about 10% of cancers occur under these circumstances. These cancers have a higher incidence at younger ages, a greater risk of lateralization or multiple occurrences, atypical behaviors, and specific histologies. Diagnosing these cancers allows for more appropriate monitoring of affected individuals—whether before or after symptoms appear—the implementation of preventive measures (such as prophylactic surgeries), the identification of at-risk family members, and the consideration of reproductive options (aimed at preventing the transmission of the mutation to offspring). 

The decision to undergo genetic testing for germline variants is based on personal and family history, but increasingly also on the possibility of personalized therapy (which is feasible for some genes). It is believed, however, that syndromes associated with a familial predisposition to cancer are underdiagnosed. In January of this year, the American Society of Clinical Oncology (ASCO) published recommendations for testing germline variants in the BRCA1 and BRCA2 genes (ideally as part of a panel that includes other genes), for all new cancer cases diagnosed in individuals ≤65 years of age and, for those over 65, depending on other factors such as family history, histology, sex, and therapeutic indication. These recommendations thus cover the majority of cancers. This contrasts with other recommendations, such as the national ones (PROGO), which are much more restrictive, using, for example, an age cutoff of <45 years as an indication for testing for most breast cancers (when age is considered in isolation). 
As sequencing costs decline, uncertainty in results decreases, and clinical applicability increases, the trend will be toward screening that is increasingly expanded to the general population.   

If you have any questions, please contact us.
We'll be happy to help.

CLINICAL PATHOLOGY LABORATORY

CLINICAL PATHOLOGY LABORATORY
EMAIL

Phone 212 693 530*

*Fixed network call charges according to your tariff

Related articles: